FDA Monthly Preview: Key April Decisions to Watch - Summary - MDSpire

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

  • By

  • Kathryn Wighton

  • March 31, 2026

  • 3 min

Share

Objective:

To highlight upcoming FDA decisions regarding expanded indications and investigational therapies across various medical specialties in April 2026.

Approach:
    Key Findings:
    • GTx-104 showed reduced hypotension incidence compared to oral nimodipine.
    • AXS-05 supported by four Phase 3 trials for Alzheimer's agitation.
    • Sparsentan reduced proteinuria but did not meet primary eGFR slope endpoint.
    • Teplizumab's application supported by Phase 4 data in young children.
    • DOR/ISL maintained high viral suppression rates in treatment-naive and switched adults.
    Interpretation:

    The upcoming FDA decisions could significantly impact treatment options in neurology, nephrology, endocrinology, and infectious diseases, with promising data supporting several investigational therapies.

    Limitations:
    • Pending FDA approval outcomes.
    • Some studies did not meet all primary endpoints.
    Conclusion:

    April 2026 may see pivotal regulatory decisions that could enhance treatment landscapes across multiple specialties.

    Sources:

Original Source(s)

FDA Monthly Preview: Key April Decisions to Watch

  • by Kathryn Wighton

  • March 31, 2026

Related Content

Diet-Dementia Link Varies by Biomarkers

Effects varied by which biomarker and diet were measured, and the study stops short of proving diet changes risk.

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

Handwriting Kinematics Differentiate Cognitive Impairment

“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”